Lung squamous cell carcinomas with basaloid histology represent a specific molecular entity

Clinical Cancer Research

Volumn 20, Issue 22, 2014, Pages 5777-5786

  Brambilla, Christian ^a,e   Laffaire, Julien ^b   Lantuejoul, Sylvie ^a   Moro Sibilot, Denis ^a   Mignotte, Hélène ^a   Arbib, Franҫois ^a   Toffart, Anne Claire ^a   Petel, Fabien ^b   Hainaut, Pierre ^c   Rousseaux, Sophie ^d   Khochbin, Saadi ^d   De Reyniès, Aurélien ^b   Brambilla, Elisabeth ^a  

^a INSTITUT ALBERT BONNIOT   (France)

^b Programme Cartes d'Identite des Tumeurs CIT   (France)

^c INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

^d INSERM   (France)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INVOLUCRIN; MESSENGER RNA; TRANSCRIPTION FACTOR SOX4; TRANSCRIPTOME;

ADULT; AGED; ARTICLE; BASALOID LUNG SQUAMOUS CELL CARCINOMA; CANCER PROGNOSIS; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVOLUCRIN GENE; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; SOX4 GENE; TRANSCRIPTOMICS; CHROMOSOME ABERRATION; CLUSTER ANALYSIS; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHROMOSOME ABERRATIONS; CLUSTER ANALYSIS; DNA COPY NUMBER VARIATIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 84916896496     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0459     Document Type: Article

References (28)

1. Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 2006;24:1679-88.
2. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75.
3. Shedden K, Taylor JMG, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14:822-7.
4. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450:893-8.
5. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012;150:1121-34.
6. Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CR, et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res 2010;16:4864-75.
7. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489: 519-25.
8. Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012;44:1104-10.
9. Brambilla E, Moro D, Veale D, Brichon PY, Stoebner P, Paramelle B, et al. Basal cell (basaloid) carcinoma of the lung: a new morphologic and phenotypic entity with separate prognostic significance. Hum Pathol 1992;23:993-1003.
10. Moro D, Brichon PY, Brambilla E, Veale D, Labat F, Brambilla C. Basaloid bronchial carcinoma. A histologic group with a poor prognosis. Cancer 1994;73:2734-9.
11. Moro-Sibilot D, Lantuejoul S, Diab S, Moulai N, Aubert A, Timsit JF, et al. Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis. Eur Respir J 2008;31:854-9.
12. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7.
13. Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 2010;28:4417-24.
14. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80.
15. Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JMG, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006;66:7466-72.
16. Lee ES, Son DS, Kim SH, Lee J, Jo J, Han J, et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res 2008;14:7397-404.
17. Roepman P, Jassem J, Smit EF, Muley T, Niklinski J, van de Velde T, et al. An immune response enriched 72-gene prognostic pro file for early-stage non-small-cell lung cancer. Clin Cancer Res 2009;15: 284-90.
18. Ma X, Rousseau V, Sun H, Lantuejoul S, Filipits M, Pirker R, et al. Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer. Mol Oncol 2014;8:555-64.
19. Sturm N, Lantuéjoul S, Laverrière MH, Papotti M, Brichon PY, Brambilla C, et al. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol 2001;32:918-25.
20. Kim DJ, Kim KD, Shin DH, Ro JY, Chung KY. Basaloid carcinoma of the lung: a really dismal histologic variant? Ann Thorac Surg 2003;76: 1833-7.
21. Rousseaux S, Debernardi A, Jacquiau B, Vitte AL, Vesin A, Nagy-Mignotte H, et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med 2013;5:186ra66.
22. Tibshirani R, Walther G, Hastie T. Estimating the number of clusters in a data set via the gap statistic. J Royal Stat Soc 2001;63:411-23.
23. Hackett NR, Shaykhiev R, Walters MS, Wang R, Zwick RK, Ferris B, et al. The human airway epithelial basal cell transcriptome. PLoS ONE 2011;6:e18378.
24. Perez-Moreno P, Brambilla E, Thomas R, Soria JC. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 2012;18:2443-51.
25. Bujnicki T, Wilczek C, Schomburg C, Feldmann F, Schlenke P, Müller-Tidow C, et al. Inhibition of Myb-dependent gene expression by the sesquiterpene lactone mexicanin-I. Leukemia 2012;26:615-22.
26. Amaru Calzada A, Todoerti K, Donadoni L, Pellicioli A, Tuana G, Gatta R, et al. The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells. Exp Hematol 2012;40:634-45.
27. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2:62ra93.
28. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS ONE 2011;6:e20351.